Arvinas clears key hurdle, showing PROTACs orally bioavailable in clinic

Putting to rest concerns regarding oral bioavailability, Arvinas showed that its first two proteolysis-targeting chimeras achieved serum levels predicted to be efficacious.

Wednesday’s presentation of Phase I data of ARV-110 for

Read the full 307 word article

How to gain access

Continue reading with a
two-week free trial.